Roche vaults to the front of the NLRP3 clinical race, paying $448M upfront to bag Inflazome
Roche is going all in on NLRP3.
The pharma giant is putting down $448 million (€380 million) upfront to snatch Novartis-backed Inflazome, which makes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
